Sentiment is coming back in.
Lucas Beaumont of Lincoln Indicators has it as a strong conviction buy read below
"Its liver cancer treatment has low market penetration and significant growth ahead. SRX has been compounding dosage sales for this treatment at 20 per cent per annum, a growth rate we don’t see letting up as estimates of market share remain in the single digits. Volatility is the investor’s friend in this case, with the recent pullback providing a 23 per cent discount to our valuation, so the stock looks compelling at current levels. SRX was trading at $27.70 on June 21."
Sentiment is coming back in. Lucas Beaumont of Lincoln...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $292.8K | 1.630M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7394560 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1260654 | 10 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |